NEW YORK (360Dx) – Finnish diagnostics company Zora Biosciences is working to expand US and European sales of its ceramide lipid-based cardiovascular risk test, CERT.

The company, which specializes in metabolomic-based diagnostics, currently offers the test throughout Finland, as well as in the US through a licensing deal with the Mayo Clinic. It is now working to launch sales in other European countries and is in discussions with other US-based clinical laboratories about licensing agreements for the test, said Reini Hurme, Zora's founder and CEO.